BI Asset Management Fondsmaeglerselskab A S Sells 11,058 Shares of Moderna, Inc. (NASDAQ:MRNA)

BI Asset Management Fondsmaeglerselskab A S decreased its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 40.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,404 shares of the company's stock after selling 11,058 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S's holdings in Moderna were worth $682,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank acquired a new stake in shares of Moderna during the fourth quarter worth $163,833,000. FMR LLC boosted its position in Moderna by 7.4% during the fourth quarter. FMR LLC now owns 18,664,634 shares of the company's stock valued at $776,075,000 after acquiring an additional 1,282,469 shares during the last quarter. Pictet Asset Management Holding SA grew its holdings in Moderna by 170.5% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company's stock worth $73,447,000 after acquiring an additional 1,113,455 shares during the period. Invesco Ltd. raised its position in shares of Moderna by 24.3% in the 4th quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock worth $208,169,000 after acquiring an additional 979,858 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Moderna by 225.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,010,758 shares of the company's stock valued at $42,027,000 after purchasing an additional 700,458 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on MRNA shares. Leerink Partners decreased their target price on Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a research note on Thursday, January 16th. Berenberg Bank lifted their price objective on shares of Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research note on Thursday, January 16th. Royal Bank of Canada reissued a "sector perform" rating and set a $40.00 target price on shares of Moderna in a research note on Tuesday, February 18th. Citigroup assumed coverage on shares of Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price target for the company. Finally, UBS Group cut their price objective on shares of Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a research report on Wednesday, February 19th. Four investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Moderna has an average rating of "Hold" and a consensus price target of $58.70.

Moderna Stock Up 1.5 %

Moderna stock traded up $0.41 during mid-day trading on Tuesday, reaching $27.87. 1,596,366 shares of the company's stock were exchanged, compared to its average volume of 7,335,223. The business's fifty day simple moving average is $30.03 and its 200 day simple moving average is $38.15. Moderna, Inc. has a one year low of $23.15 and a one year high of $170.47. The firm has a market capitalization of $10.77 billion, a PE ratio of -3.00 and a beta of 2.23.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.